A part of MilliporeSigma

CC4000 | Urokinase-type Plasminogen Activator

100 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Specifications Table

      Key ApplicationsEntrez Gene NumberSpeciesUni Prot Number
      ACT NM_002658.2 Human P00749
      Catalogue NumberCC4000
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionUrokinase-type Plasminogen Activator
      OverviewA thrombolytic agent that converts plasminogen to plasmin. A mixture of high molecular weight and low molecular weight urokinase.
      Alternate Names
      • uPA
      Product Information
      PresentationLyophilized from 200 mM manitol, 100 mM NaCl, 50 mM Tris-HCl, pH 7.5 and 0.1 % PEG.
      Key Applications
      • Activity Assay
      Biological Information
      PurityOver 98%SDS-PAGE:

      High molecular weight urokinase (54 kD) 40%

      Low molecular weight urokinase (33 kD) 50%

      Transitory forms of urokinase 10%
      SourcePrepared from urine of healthy individuals
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer disease and also with decreased affinity for fibrin-binding. The protein encoded by this gene converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. This gene's proprotein is cleaved at a Lys-Ile bond by plasmin to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor.
      Gene Symbol
      • PLAU
      • UPA
      • URK
      • u-PA
      • uPA
      • ATF
      • EC [Contains: Urokinase-type plasminogen activator long chain A
      • Urokinase-type plasminogen activator short chain A
      • Urokinase-type plasminogen activator chain B].
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P00749 # Specifically cleave the zymogen plasminogen to form the active enzyme plasmin.
      SIZE: 431 amino acids; 48525 Da
      SUBUNIT: Found in high and low molecular mass forms. Each consists of two chains, A and B. The high molecular mass form contains a long chain A which is cleaved to yield a short chain A. Binds LRP1B; binding is followed by internalization and degradation. Interacts with MRC2. Interacts with PLAUR.
      TISSUE SPECIFICITY: Expressed in the prostate gland and prostate cancers.
      PTM: Phosphorylation of Ser-158 and Ser-323 abolishes proadhesive ability but does not interfere with receptor binding.
      SIMILARITY: SwissProt: P00749 ## Belongs to the peptidase S1 family. & Contains 1 EGF-like domain. & Contains 1 kringle domain. & Contains 1 peptidase S1 domain.
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsReconstitute using 200-400 μL dH2O. Store at -20°C. Following reconstitution, aliquot and freeze (-70°C). This product is stable for 2 year as supplied. Stock solutions are stable for up to 6 months at -70°C.
      Packaging Information
      Material Size100 µg
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      UROKINASE, HUMAN URINE - 2150709 2150709
      UROKINASE, HUMAN URINE - 2386971 2386971
      UROKINASE, HUMAN URINE - 2420339 2420339
      UROKINASE, HUMAN URINE - 2266451 2266451
      UROKINASE, HUMAN URINE - 2276272 2276272
      UROKINASE, HUMAN URINE - 2327676 2327676
      UROKINASE, HUMAN URINE - 2488719 2488719
      UROKINASE, HUMAN URINE -2558373 2558373
      UROKINASE, HUMAN URINE -2607635 2607635
      UROKINASE, HUMAN URINE -2676257 2676257
      UROKINASE, HUMAN URINE -2710736 2710736
      UROKINASE, HUMAN URINE -2723037 2723037


      Reference overviewPub Med ID
      Identification of regulatory Hck and PAI-2 proteins in the monocyte response to PEG-containing matrices.
      Sean T Zuckerman,James F Brown,Weiyuan J Kao
      Biomaterials 30 2009

      Show Abstract Full Text Article
      19443025 19443025
      Thrombolytic therapy: a comparison between urokinase and streptokinase. From a national cooperative study.
      Bell, W R
      Semin. Thromb. Hemost., 2: 1-13 (1975) 1975

      798268 798268
      Assay methods and standard preparations for plasmin, plasminogen and urokinase in purified systems, 1967-1968.
      Johnson, A J, et al.
      Thrombosis et diathesis haemorrhagica, 21: 259-72 (1969) 1969

      4238780 4238780

      Data Sheet

      Urokinase-type Plasminogen Activator - Data Sheet